| scholarly article | Q13442814 |
| P2093 | author name string | David W Speicher | |
| Frank Vitzthum | |||
| Gerard Siest | |||
| Craig A Gelfand | |||
| Daniel W Chan | |||
| Brian B Haab | |||
| Alex J Rai | |||
| Bruce C Haywood | |||
| David J Warunek | |||
| Graham B I Scott | |||
| Harald Tammen | |||
| Jizu Yi | |||
| Mark D Schuchard | |||
| Peter Schulz-Knappe | |||
| Richard J Mehigh | |||
| Steven L Cockrill | |||
| P433 | issue | 13 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 3262-3277 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Proteomics | Q15614164 |
| P1476 | title | HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples | |
| P478 | volume | 5 |
| Q36381232 | 2D gel blood serum biomarkers reveal differential clinical proteomics of the neurodegenerative diseases |
| Q47101230 | 5D proteomic approach for the biomarker search in plasma: Acute myeloid leukaemia as a case study |
| Q57064146 | A Framework for Development of Useful Metabolomic Biomarkers and Their Effective Knowledge Translation |
| Q37651691 | A Timely Shift from Shotgun to Targeted Proteomics and How It Can Be Groundbreaking for Cancer Research. |
| Q91682228 | A comparative protein analysis of lung cancer, along with three controls using a multidimensional proteomic approach |
| Q31125985 | A method for improving SELDI-TOF mass spectrometry data quality |
| Q84358736 | A proteomic approach for plasma biomarker discovery with 8-plex iTRAQ labeling and SCX-LC-MS/MS |
| Q33514848 | A proteomic approach for plasma biomarker discovery with iTRAQ labelling and OFFGEL fractionation |
| Q35879468 | A proteomic approach to obesity and type 2 diabetes |
| Q50356125 | A proteomics-driven assay defines specific plasma protein signatures in different stages of Ménière's disease. |
| Q93112495 | A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia |
| Q33436829 | Adapting mass spectrometry-based platforms for clinical proteomics applications: The capillary electrophoresis coupled mass spectrometry paradigm |
| Q33433660 | Advanced proteomic technologies for cancer biomarker discovery |
| Q34463818 | An automated plasma protein fractionation design: high-throughput perspectives for proteomic analysis |
| Q27024427 | An update on microRNAs as colorectal cancer biomarkers: where are we and what's next? |
| Q42355096 | Analysis of endoscopic pancreatic function test (ePFT)-collected pancreatic fluid proteins precipitated via ultracentrifugation |
| Q37257661 | Analysis of human plasma proteins: a focus on sample collection and separation using free-flow electrophoresis |
| Q64227228 | Analysis of the Glycosylation Profile of Disease-Associated Water-Soluble Prion Protein Using Lectins |
| Q35196711 | Analysis of the differences of serum protein mass spectrometry in patients with triple negative breast cancer and non-triple negative breast cancer |
| Q33304961 | Analytical validation of serum proteomic profiling for diagnosis of prostate cancer: sources of sample bias |
| Q36478274 | Antibody orientation at bacterial surfaces is related to invasive infection. |
| Q37691267 | Application of mass spectrometry-based proteomics for biomarker discovery in neurological disorders |
| Q33467523 | Approaching clinical proteomics: current state and future fields of application in fluid proteomics |
| Q28235692 | Assessing bias in experiment design for large scale mass spectrometry-based quantitative proteomics |
| Q49931504 | Assessment by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of the Effects of Preanalytical Variables on Serum Peptidome Profiles Following Long-Term Sample Storage. |
| Q34462735 | Before you analyze a human specimen, think quality, variability, and bias |
| Q42609228 | Biobanking and international interoperability: samples |
| Q34977057 | Biobanking for better healthcare |
| Q34396142 | Biomarker analysis of stored blood products: emphasis on pre-analytical issues |
| Q36950431 | Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays |
| Q48921077 | Blood Bio-Sampling Procedures for Multiplex Biomarkers Studies |
| Q38869519 | Blood Sampling and Preparation Procedures for Proteomic Biomarker Studies of Psychiatric Disorders |
| Q38068925 | Breast cancer biomarkers: proteomic discovery and translation to clinically relevant assays |
| Q33579184 | Cardiovascular proteomics: implications for clinical applications |
| Q99634733 | Challenges and Opportunities in Clinical Applications of Blood-Based Proteomics in Cancer |
| Q33520447 | Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. |
| Q46340998 | Characterization of the Low-Molecular-Weight Human Plasma Peptidome. |
| Q64238225 | Circulating proteomic panels for diagnosis and risk stratification of acute-on-chronic liver failure in patients with viral hepatitis B |
| Q30487959 | Classification-based comparison of pre-processing methods for interpretation of mass spectrometry generated clinical datasets. |
| Q57281984 | Clinical Proteomics for Post-Hematopoeitic Stem Cell Transplantation Outcomes |
| Q38802991 | Clinical applications of MS-based protein quantification |
| Q38753775 | Clinical proteomics-driven precision medicine for targeted cancer therapy: current overview and future perspectives |
| Q38202166 | Colorectal cancer biomarker discovery and validation using LC-MS/MS-based proteomics in blood: truth or dare? |
| Q37578725 | Colorectal cancer biomarkers: to be or not to be? Cautionary tales from a road well travelled |
| Q31080442 | Comparing the MicroRNA spectrum between serum and plasma |
| Q51570044 | Comparing the applicability of CGE-on-the-chip and SDS-PAGE for fast pre-screening of mouse serum samples prior to proteomics analysis. |
| Q34166788 | Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS. |
| Q45272217 | Comparison of proteins in whole blood and dried blood spot samples by LC/MS/MS. |
| Q37592722 | Comparison of serum, EDTA plasma and P100 plasma for luminex-based biomarker multiplex assays in patients with chronic obstructive pulmonary disease in the SPIROMICS study |
| Q36922917 | Comprehensive analysis of the N and C terminus of endogenous serum peptides reveals a highly conserved cleavage site pattern derived from proteolytic enzymes |
| Q33743194 | Data Management and Data Integration in the HUPO Plasma Proteome Project |
| Q28546842 | Degradation and Stabilization of Peptide Hormones in Human Blood Specimens |
| Q38113846 | Delineating the synovial fluid proteome: recent advancements and ongoing challenges in biomarker research |
| Q41656530 | Development of a high-throughput UHPLC-MS/MS (SRM) method for the quantitation of endogenous glucagon from human plasma |
| Q41145142 | Diagnostic accuracy of porcine acute phase proteins in meat juice for detecting disease at abattoir. |
| Q33958684 | Differential analysis of N-glycoproteome between hepatocellular carcinoma and normal human liver tissues by combination of multiple protease digestion and solid phase based labeling |
| Q38167708 | Differential expression of serum/plasma proteins in various infectious diseases: specific or nonspecific signatures. |
| Q39413046 | Direct Assessment of Plasma/Serum Sample Quality for Proteomics Biomarker Investigation |
| Q36569667 | Discovery and validation of graft-versus-host disease biomarkers |
| Q51963124 | Discovery of cancer biomarkers using antibody arrays. |
| Q38822316 | Discovery of urine biomarkers for bladder cancer via global metabolomics. |
| Q37460195 | Early Detection of Cancer: Immunoassays for Plasma Tumor Markers |
| Q91972747 | Effect of haptoglobin on the treatment of chronic hepatitis B with interferon |
| Q33990546 | Effect of storage temperature as a preanalytical variable on the lens crystallins protein quality for proteomic studies |
| Q36562084 | Effects of preanalytical variables on peptide and protein measurements in human serum and plasma: implications for clinical proteomics |
| Q33850682 | Elevated plasma albumin and apolipoprotein A-I oxidation under suboptimal specimen storage conditions |
| Q38960512 | Enhancing translational research in paediatric rheumatology through standardization |
| Q30372676 | Evaluating the effects of preanalytical variables on the stability of the human plasma proteome |
| Q35125470 | Evaluation of protease inhibitors containing tubes for MS-based plasma peptide profiling studies. |
| Q35417685 | Extracellular microRNA: a new source of biomarkers |
| Q33577873 | Feature detection techniques for preprocessing proteomic data |
| Q45887105 | Freeze-dried plasma proteins are stable at room temperature for at least 1 year. |
| Q36580350 | Frozen tissue biobanks. Tissue handling, cryopreservation, extraction, and use for proteomic analysis |
| Q34116114 | Functional protease profiling for diagnosis of malignant disease |
| Q56523849 | Genome Database of the Latvian Population (LGDB): Design, Goals, and Primary Results |
| Q26751068 | Genomics, microRNA, epigenetics, and proteomics for future diagnosis, treatment and monitoring response in upper GI cancers |
| Q36208968 | Global stability of plasma proteomes for mass spectrometry-based analyses. |
| Q26824540 | Graft-versus-host disease biomarkers: omics and personalized medicine |
| Q24289435 | Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research |
| Q33395871 | Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients. |
| Q33900798 | High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. |
| Q33579375 | High-throughput and targeted in-depth mass spectrometry-based approaches for biofluid profiling and biomarker discovery |
| Q42086672 | High-throughput studies of protein glycoforms using antibody-lectin sandwich arrays |
| Q34440014 | Highly efficient human serum filtration with water-soluble nanoporous nanoparticles. |
| Q33262623 | Human body fluid proteome analysis |
| Q37142407 | Identification of ganglioside GM2 activator playing a role in cancer cell migration through proteomic analysis of breast cancer secretomes |
| Q37280282 | Immunodepletion plasma proteomics by tripleTOF 5600 and Orbitrap elite/LTQ-Orbitrap Velos/Q exactive mass spectrometers |
| Q33776978 | Impact of the storage temperature on human plasma proteomic analysis: implications for the use of human plasma collections in research. |
| Q41943984 | In situ characterization of nanoparticle biomolecular interactions in complex biological media by flow cytometry |
| Q41361822 | In-Depth, Reproducible Analysis of Human Plasma Using IgY 14 and SuperMix Immunodepletion |
| Q35169891 | In-depth analysis of a plasma or serum proteome using a 4D protein profiling method |
| Q33439145 | Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS). |
| Q38928631 | Intact stable isotope labeled plasma proteins from the SILAC-labeled HepG2 secretome |
| Q41513462 | Integrative analysis for the discovery of lung cancer serological markers and validation by MRM-MS. |
| Q37607345 | Interferences from blood collection tube components on clinical chemistry assays |
| Q37393371 | Interlaboratory studies and initiatives developing standards for proteomics |
| Q33605010 | Investigation of the ovarian and prostate cancer peptidome for candidate early detection markers using a novel nanoparticle biomarker capture technology |
| Q27015012 | LC-MS-based metabolomics |
| Q38694933 | Low-Molecular-Weight Plasma Proteome Analysis Using Top-Down Mass Spectrometry |
| Q38183147 | MRM for the verification of cancer biomarker proteins: recent applications to human plasma and serum |
| Q37552845 | Mass Spectrometry-based Proteomics and Peptidomics for Systems Biology and Biomarker Discovery |
| Q38203040 | Mass spectrometry based biomarker discovery, verification, and validation--quality assurance and control of protein biomarker assays |
| Q28307595 | Mass spectrometry in cancer biomarker research: a case for immunodepletion of abundant blood-derived proteins from clinical tissue specimens |
| Q64121030 | Mass spectrometry-based intraoperative tumor diagnostics |
| Q35855485 | Mass spectrometry-based proteomics for translational research: a technical overview. |
| Q37848311 | Mass spectrometry-based proteomics of endoscopically collected pancreatic fluid in chronic pancreatitis research |
| Q37431947 | Mesoporous silica chip: enabled peptide profiling as an effective platform for controlling bio-sample quality and optimizing handling procedure |
| Q37810156 | Multiplexed Antibody Arrays for The Discovery and Validation of Glycosylated Protein Biomarkers |
| Q58570772 | Needle lost in the haystack: multiple reaction monitoring fails to detect Treponema pallidum candidate protein biomarkers in plasma and urine samples from individuals with syphilis |
| Q35680829 | Novel serum and urine markers for pediatric appendicitis |
| Q34475498 | OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis. |
| Q35180727 | Opportunities and challenges of proteomics in pediatric patients: circulating biomarkers after hematopoietic stem cell transplantation as a successful example |
| Q41985686 | Optimized sample preparation of endoscopic collected pancreatic fluid for SDS-PAGE analysis |
| Q34214393 | Optimizing a proteomics platform for urine biomarker discovery |
| Q36505671 | Peptide profiling of cerebrospinal fluid by mass spectrometry |
| Q33234191 | Peptidomic analysis of breast cancer reveals a putative surrogate marker for estrogen receptor-negative carcinomas |
| Q36950443 | Peptidomics analysis of human blood specimens for biomarker discovery |
| Q64235676 | Plasma Peptidome Pattern of Breast Cancer Using Magnetic Beads-Based Plasma Fractionation and MALDI-TOF MS: A Case Control Study in Egypt |
| Q90366678 | Plasma Proteome Profiling to detect and avoid sample-related biases in biomarker studies |
| Q37213002 | Plasma and cerebrospinal proteomes from children with cerebral malaria differ from those of children with other encephalopathies |
| Q35169971 | Plasma biomarker discovery using 3D protein profiling coupled with label-free quantitation |
| Q84061239 | Plasma level of lipopolysaccharide-binding protein is indicative of acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation |
| Q34122107 | Plasma membrane proteomics and its application in clinical cancer biomarker discovery |
| Q35041471 | Plasma peptide biomarker discovery for amyotrophic lateral sclerosis by MALDI-TOF mass spectrometry profiling |
| Q38310935 | Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis. |
| Q47159796 | Plasma proteomics reveals coagulation, inflammation, and metabolic shifts in H-type hypertension patients with and without acute ischemic stroke |
| Q36841871 | Plasma/serum proteomics: pre-analytical issues. |
| Q38038568 | Potential biomarkers for early detection of acute graft-versus-host disease |
| Q38164428 | Pre-analytical and analytical variability in absolute quantitative MRM-based plasma proteomic studies |
| Q36858663 | Pre-analytical stability of the plasma proteomes based on the storage temperature |
| Q39116735 | Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer |
| Q34033258 | Predicting prostate cancer biochemical recurrence using a panel of serum proteomic biomarkers |
| Q34248807 | Prioritization of biomarker targets in human umbilical cord blood: identification of proteins in infant blood serving as validated biomarkers in adults |
| Q33642003 | ProteoMiner™ and SELDI-TOF-MS: a robust and highly reproducible combination for biomarker discovery from whole blood serum |
| Q94503846 | Proteome Multimarker Panel With Multiple Reaction Monitoring-Mass Spectrometry for Early Detection of Hepatocellular Carcinoma |
| Q37781730 | Proteomic Analysis in Multiple Myeloma Research |
| Q39076980 | Proteomic Profiling of Serial Prediagnostic Serum Samples for Early Detection of Colon Cancer in the U.S. Military |
| Q37636447 | Proteomic Workflows for Biomarker Identification Using Mass Spectrometry - Technical and Statistical Considerations during Initial Discovery |
| Q37352025 | Proteomic analysis of human plasma and blood cells in nutritional studies: development of biomarkers to aid disease prevention |
| Q46445180 | Proteomic analysis of protein adsorption capacity of different haemodialysis membranes |
| Q37817106 | Proteomic analysis of serum, plasma, and lymph for the identification of biomarkers |
| Q37579903 | Proteomic approaches in neuroblastoma: a complementary clinical platform for the future |
| Q35848791 | Proteomic approaches to dissect platelet function: Half the story |
| Q33360168 | Proteomic studies of early-stage and advanced ovarian cancer patients |
| Q33891197 | Proteomic technologies for the identification of disease biomarkers in serum: advances and challenges ahead |
| Q84992972 | Proteomics and Pitfalls in the Search for Potential Biomarkers of Abdominal Aortic Aneurysms |
| Q36445586 | Proteomics and heart disease: identifying biomarkers of clinical utility |
| Q38084362 | Proteomics applied to transfusion plasma: the beginning of the story |
| Q36505667 | Proteomics approaches to urologic diseases |
| Q50434514 | Proteomics in Ménière disease. |
| Q36787244 | Proteomics in atherothrombosis: a future perspective |
| Q38253149 | Proteomics in paediatric cardiac surgery: is a personalised approach feasible? |
| Q28297411 | Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery |
| Q37812799 | Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics |
| Q37239923 | Proteomics-based identification and validation of novel plasma biomarkers phospholipid transfer protein and mannan-binding lectin serine protease-1 in age-related macular degeneration |
| Q40356956 | Quality assurance of metabolomics. |
| Q47165512 | Random and independent sampling of endogenous tryptic peptides from normal human EDTA plasma by liquid chromatography micro electrospray ionization and tandem mass spectrometry. |
| Q57534300 | Recent advances in microchip-mass spectrometry for biological analysis |
| Q37810186 | Recent progress in selected reaction monitoring MS-driven plasma protein biomarker analysis |
| Q35610458 | Relative quantification of several plasma proteins during liver transplantation surgery |
| Q30385237 | Review: the use of proteomics as a research methodology for studying cancer-related fatigue: a review. |
| Q59340320 | SEPROGADIC - serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy |
| Q37155233 | SRM targeted proteomics in search for biomarkers of HCV-induced progression of fibrosis to cirrhosis in HALT-C patients |
| Q35145781 | Sample collection in clinical proteomics--proteolytic activity profile of serum and plasma |
| Q36682379 | Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry |
| Q37901027 | Sample preparation prior to the LC-MS-based metabolomics/metabonomics of blood-derived samples |
| Q41534186 | Serum fibronectin distinguishes the early stages of hepatocellular carcinoma |
| Q35151719 | Serum proteomic analysis reveals high frequency of haptoglobin deficiency and elevated thyroxine level in heroin addicts |
| Q89983540 | Serum proteomics of active tuberculosis patients and contacts reveals unique processes activated during Mycobacterium tuberculosis infection |
| Q34268788 | Specific Investigation of Sample Handling Effects on Protease Activities and Absolute Serum Concentrations of Various Putative Peptidome Cancer Biomarkers |
| Q37128329 | Standard operating procedures for serum and plasma collection: early detection research network consensus statement standard operating procedure integration working group |
| Q34151647 | Standardizing the structure of stroke clinical and epidemiologic research data: the National Institute of Neurological Disorders and Stroke (NINDS) Stroke Common Data Element (CDE) project |
| Q38268593 | State of the art of 2D DIGE. |
| Q36198969 | Systematic comparison of fractionation methods for in-depth analysis of plasma proteomes |
| Q33289727 | Technology insight: the application of proteomics in gastrointestinal disease |
| Q57267915 | The Future: Translation from Discovery to the Clinic - Roles of HUPO and Industry in Biomarker Discovery |
| Q51021753 | The NCI Biospecimen Research Network. |
| Q33740788 | The discovery and validation of colorectal cancer biomarkers |
| Q48299927 | The effect of different protease inhibitors on stability of parathyroid hormone, insulin, and prolactin levels under different lag times and storage conditions until analysis. |
| Q28484137 | The effect of pre-analytical variability on the measurement of MRM-MS-based mid- to high-abundance plasma protein biomarkers and a panel of cytokines |
| Q38822395 | The landscape of viral proteomics and its potential to impact human health |
| Q34171477 | The potential role of ORM2 in the development of colorectal cancer |
| Q47158443 | The proteins cleaved by endogenous tryptic proteases in normal EDTA plasma by C18 collection of peptides for liquid chromatography micro electrospray ionization and tandem mass spectrometry |
| Q36432402 | The proteomics big challenge for biomarkers and new drug-targets discovery |
| Q34203863 | Thermal stabilization of tissues and the preservation of protein phosphorylation states for two-dimensional gel electrophoresis |
| Q30855514 | Thrombin induces broad spectrum proteolysis in human serum samples |
| Q58260463 | Time-Dependent and Sample-to-Sample Variations in Human Plasma Peptidome are Both Minimized Through Use of Protease Inhibitors |
| Q34961484 | Time-of-flight mass spectrometry in screening serum-specific protein in patients with scrotal Paget's disease |
| Q33912503 | Towards proteome standards: the use of absolute quantitation in high-throughput biomarker discovery |
| Q54223894 | Transcoronary gradient of plasma microRNA 423-5p in heart failure: evidence of altered myocardial expression. |
| Q34351046 | Transferrin coated nanoparticles: study of the bionano interface in human plasma |
| Q56744839 | Unravelling Malaria Antigen Binding to Antibody-Gold Nanoparticle Conjugates |
| Q57556407 | Use of genome-wide high-throughput technologies in biomarker development |
| Q33400847 | Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study |
| Q33437720 | Variation in protein levels obtained from human blood cells and biofluids for platelet, peripheral blood mononuclear cell, plasma, urine and saliva proteomics |
| Q33257826 | When does a fingerprint constitute a diagnostic? |
| Q26827259 | World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research |
| Q34504341 | World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonization Project: III. Fluid biospecimen collection, processing, and storage in endometriosis research |
| Q38315546 | Wound samples: moving towards a standardised method of collection and analysis |
| Q80652848 | [Use of antibodies arrays in the study of bladder cancer] |
| Q38855553 | iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer |
| Q28553838 | α-Mangostin Extraction from the Native Mangosteen (Garcinia mangostana L.) and the Binding Mechanisms of α-Mangostin to HSA or TRF |
Search more.